<DOC>
	<DOCNO>NCT00921063</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy PD 0332334 compare placebo treatment Generalized Anxiety Disorder adult population</brief_summary>
	<brief_title>A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Healthy male female diagnosis Generalized Anxiety Disorder ( GAD ) ( Diagnostic Statistical ManualIV [ DSMIV ] , 300.02 ) . HAMA Total Score ≥20 item # 1 HAMD ( depressed mood score ) ≤2 Screening Baseline/Randomization . Current diagnosis ( within 6 month ) Major Depressive Disorder ; Obsessive Compulsive Disorder ; Panic Disorder ; Posttraumatic Stress Disorder ; Anorexia ; Bulimia ; Caffeineinduced anxiety disorder ; Any follow past current diagnosis : Schizophrenia ; Psychotic Disorder ; Delirium , Dementia , Bipolar Schizoaffective Disorder ; Cyclothymic Disorder ; Dissociative Disorders ; Antisocial borderline personality disorder Current use psychotropic medication ( i.e. , drug normally prescribe depression , mania , anxiety , insomnia , psychosis ) could discontinue 2 week prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>